Protection from Microscopic Bugs
Last summer I sent you an e-Alert (“In the Trenches with the Superbugs” 8/6/02) telling you about the war being waged on a microscopic level inside our own bodies – a war with bacteria so determined to survive that they adapt to whatever antibiotics we invent to fight them. This frightening scenario has turned into a dangerous, ongoing battle, just as we at HSI first told you it would 6 years ago. So, in case you thought we were just playing the fear card, keep reading. It’s almost worse than we predicted.
I’ve asked HSI Panelist, Allan Spreen, M.D., to give us his take on the situation and offer some advice on how we can best protect ourselves from superbugs, and bugs in general.
The more things change
Everyone living this side of a cave has heard about drug resistant bacteria. It’s practically a catch phrase that CNN throws at us from the medical side of things when there’s no major headline to play with.
Keep in mind that the reputation of modern medicine to deliver ‘miracle’ drugs is built almost entirely on antibiotic successes. Starting with penicillin for pneumococcal pneumonia (once highly fatal, then becoming a minor player in terms of mortality statistics), the antibiotic is the agent that really opened the world’s eyes to drug therapy successes. If there ever was a real problem with one type not working, there was always a new one, or even an entire new class of antibiotic, waiting in the wings to take over and blow our minds again.
Well, that’s changing.
Superbugs at large
HSI recently wrote about the first reported case of a new bacterium that is completely resistant to vancomycin – a powerful antibiotic that’s been so effective that it’s referred to as a “last line of defense.” This new drug-resistant bacterium is a variation on Staphylococcus aureus (SA), a superbug that sometimes causes wound infections. The Centers for Disease Control (CDC) led the bacterial analysis in this case, and said that more mutated organisms like SA are expected. New antibiotics under development have already encountered mutated strains of SA that are resistant to the new drugs.
Even more recently the Wall Street Journal (9/27/02) published a cute little piece entitled ‘Drug-Resistant Bacteria Cases No Longer Are Just in Hospitals.’ An international panel of experts on the topic warned that superbugs once confined to hospitals are now on the loose “in the general community.” This news comes to us from an International Forum on Antibiotic Resistance, so somebody up there is worried. Dr. Gary Doern, professor of medicine and director of clinical microbiology at the University of Iowa, summarized the data this way, “There are now patients with pneumococcal infections for whom there is no antibiotic.” He also mentioned that methicillin-resistant SA, originally only encountered in hospitals, is now occurring in some communities up to 30% of the time.
Methicillin, penicillin, vancomycin, ciprofloxacin, whateverthe drug company gurus will cook up a new class of antibiotic and away we’ll go – no problem.
Well, maybe just a little problem.
Bottom of the barrel
BiomedNet News, an Internet news service for the scientific community, expanded on some details the Wall Street Journal omitted. In the September 26 edition they have Dr. Doern saying a few other things. It seems that the speed with which bacteria develop antibiotic resistance is far faster than the hotshots figured. In the last 2 years drug resistance to fluoroquinolone antibiotics (Cipro is a member of this class) has nearly tripled. Said Doern, “Literally as we speak, fluoroquinolones are being compromised by resistance.”
But here’s the article’s kicker: “This time, Doern says, no new drugs are forthcoming.” Again quoting directly from the article (they do it so much better than I), “Developing a new antibiotic can cost close to a billion dollars, and the US Food and Drug Administration (FDA) has tightened rules for approval. The ketolide Ketek, manufactured by Aventis and awaiting approval in February 2003, had to be tested with 25,000 patients in its phase III trial before being submitted for FDA approval, Doern noted. Ketek is ‘arguably the only new antibiotic – and that’s no exaggeration – we’re likely to see in the next 10 years.'”
The alternative
It’s now evident that bacteria contain the genetic material to resist alien biochemistries synthetic drug efforts to kill them. This does not, however, seem to be the case in the area of natural agents possessing antibacterial properties, and those agents do exist. We hear little about them because of the fact that they are not patentable and therefore have no profit potential, at least nowhere near the level drug companies desire.
Tomorrow I’ll tell you about four natural anti-bacterial (and anti-viral) agents that have a lot of what many would call “anecdotal evidence” behind them. Nonetheless, they may be our only hope of being pulled out of the fire.
Good Health,
Allan N. Spreen, MD
Stay tuned
I know there’s a great deal of interest among HSI members on this topic. Many members have sent e-mails, and there’s currently a discussion in the HSI Forum with more than 60 postings under the title of “Natural Antibiotics.” So, I’ve asked Dr. Spreen to elaborate on those four natural anti-bacterial agents that are available in any health food store. Look for that in your inbox tomorrow.
